Trial Profile
Phase II study of XELIRI and bevacizumab as second-line therapy in patients with metastatic colorectal cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 30 Aug 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Capecitabine (Primary) ; Irinotecan (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- 23 Aug 2021 Status changed from recruiting to active, no longer recruiting.
- 29 Jan 2013 New trial record